Disease: smoking addiction

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US

mycolabadmin

Researchers are studying psilocybin, a compound from certain mushrooms, as a potential treatment for depression, anxiety, and addiction. The United States has significantly more clinical trials underway than the European Union, reflecting different regulatory approaches and funding levels. While US trials progress faster, EU trials emphasize safety and careful evaluation. Both regions show promising results when psilocybin is combined with professional psychological support in controlled settings.

Read More »

Moral enhancement and cheapened achievement: Psychedelics, virtual reality and AI

mycolabadmin

This paper examines whether using drugs or technology to become a more moral person cheapens the value of that achievement, similar to debates about ‘cheating’ through cognitive enhancers. The authors argue that realistic applications of psychedelics, virtual reality, and AI—when used to facilitate rather than replace moral learning—can actually preserve what makes moral improvement valuable: our own effort, reflection, and engagement with moral reasons.

Read More »

The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review

mycolabadmin

This review examines how psilocybin, a compound found in certain mushrooms, may help people recover from traumatic brain injuries. The research suggests that psilocybin could reduce harmful inflammation in the brain, help the brain form new connections to compensate for damage, and improve mood and depression commonly experienced after brain injuries. While promising, the authors emphasize that more clinical trials are needed to confirm safety and effectiveness before psilocybin can be used to treat brain injury patients.

Read More »
Scroll to Top